New combo tackles Tough-to-Treat colorectal cancer
NCT ID NCT03711058
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of two drugs—copanlisib and nivolumab—in 48 adults with advanced solid tumors, specifically a type of colorectal cancer called MSS that usually doesn't respond to immunotherapy alone. The goal was to see if the combination could shrink tumors and to find the safest dose. The study is now complete, and results will help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Copanlisib and nivolumab
What this could lead to
If this combination works, it could offer a new treatment option for people with advanced MSS colorectal cancer, a type that typically does not respond to immunotherapy alone.
What could go wrong
This was an early-phase trial with only 48 participants, so results may not apply to everyone. The drugs can cause serious side effects like lung inflammation and liver problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR METASTATIC MICROSATELLITE STABLE (MSS) SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States